2021 San Antonio Breast Cancer Symposium (SABCS 2021)

Sunshine vitamin, calcium may help avert bone loss associated with AIs

Elvira Manzano, 20220118000000

Supplementation with vitamin D, otherwise called sunshine vitamin, and calcium may help women with breast cancer protect against bone loss associated with aromatase inhibitors (AIs), suggests a 5-year follow-up study from Brazil.

Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC

Roshini Claire Anthony, 20220112180001

Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.

Pyrotinib + capecitabine extends OS in metastatic breast cancer

Roshini Claire Anthony, 20220110150001

Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.

Metformin disappoints in early breast cancer

Elvira Manzano, 20220110000000

Adjuvant treatment with metformin does not improve outcomes in most patients with early breast cancer in a phase III study, suggesting that metformin should not be used as a breast cancer treatment in these patients.

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

Audrey Abella, 20220104100000

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Processed food linked to multiple cancer risk

Pearl Toh, 20220102090000

Dietary intake of the common food additive nitrates and nitrites, trans fatty acids, and artificial sweeteners was associated with an increased risk of multiple cancers, according to data from the large NutriNet-Santé cohort presented at SABCS 2021.

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer

Audrey Abella, 20211230100000

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.

Ovarian suppression + AIcombo therapy prevents recurrence in premenopausal breast cancer

Ovarian suppression + AI prevents recurrence in premenopausal breast cancer over long term

Pearl Toh, 20211228140100

The benefits in terms of prolonged disease-free survival (DFS) and reduced risk of recurrence with ovarian function suppression (OFS) persisted over 12–13 years in premenopausal women with hormone receptor-positive (HR+) breast cancer, according to new data from the TEXT and SOFT randomized trials presented at SABCS 2021.

Adjuvant palbociclib + ET does not improve outcomes vs ET alone in early breast cancer

Christina Lau, 20211215034026

Adjuvant palbociclib in combination with endocrine therapy (ET) does not improve invasive disease-free survival (iDFS) or secondary endpoints vs ET alone in patients with hormone receptor–positive, HER2-negative early breast cancer, final results of the phase III PALLAS trial have shown.